Researchers at the University of California, Davis have developed non-invasive methods for intranasally delivering the drug allopregnanolone.

Researchers at the University of California, Davis have developed an advanced multi x-ray source array system employing dual cathode designs that enhance computed tomography (“CT”) imaging by enabling pulsed, spatially multiplexed x-ray emission with reduced artifacts.

Researchers at the University of California, Davis and the Chiba University Center for Forensic Mental Health in Japan have collaborated to develop an enzyme inhibitor that prevents the onset of neurodevelopmental disorders.

Researchers at the University of California, Davis have developed a therapeutic approach to prevent and treat cancer cachexia by inhibiting soluble epoxide hydrolase, promoting resolution of systemic inflammation, mitigating muscle wasting, and improving survival outcomes in preclinical models without inducing toxicity or immunosuppression.

Researchers at the University of California, Davis have developed a technology that introduces an approach to creating semi-living, non-replicating cellular systems for advanced therapeutic applications.

Researchers at the University of California, Davis have developed a vaccine platform utilizing non-replicating, metabolically active Cyborg Bacterial Pathogens to combat multi-antibiotic-resistant bacteria.

Researchers at the University of California, Davis, have developed a method to prepare chemically well-defined HSA-drug conjugates, such that ligation can occur in vitro or in vivo under physiological condition.

Researchers at the University of California, Davis have developed a novel stem cell gene therapy approach utilizing a modified SYNGAP1 protein to treat Synaptic Ras GTPase Activating Protein 1-related intellectual disability (SRID).